Hypokalaemia and outcomes in older patients hospitalized for heart failure.

Authors
Valentova, Miroslava
Patel, Samir
Lam, Phillip H
et al.

Publication Date
2020-06-01

DOI
10.1002/ehf2.12666

Peer reviewed
Hypokalaemia and outcomes in older patients hospitalized for heart failure

Miroslava Valentova1,2, Samir Patel3,4, Phillip H. Lam3,5,6, Charles Faselis3,4, Cherinne Arundel3,4, Gregg C. Fonarow7, Yan Cheng3,8, Richard M. Allman4,9, Stephan von Haehling1,2, Stefan D. Anker10 and Ali Ahmed3,4,5*

1Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; 2German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany; 3Department of Medicine, Veterans Affairs Medical Center, Washington, DC, USA; 4Department of Medicine, George Washington University, Washington, DC, USA; 5Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; 6Division of Cardiology, University of California, Los Angeles, CA, USA 7Biomedical Informatics Center, George Washington University, Washington, DC, USA; 8Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 9Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätmedizin Berlin, Berlin, Germany

Abstract

Aims Hypokalaemia is a risk factor for ventricular arrhythmias and sudden death in ambulatory patients with chronic heart failure (HF). The objective of this study was to examine the association between hypokalaemia and outcomes in hospitalized patients with decompensated HF in whom sudden death is less common.

Methods and results Of the 5881 hospitalized patients with HF, 1052 had consistent hypokalaemia (both admission and discharge serum potassium <4.0 mmol/L), and 2538 had consistent normokalaemia (both admission and discharge serum potassium 4.0–5.0 mmol/L). Propensity scores for consistent hypokalaemia, estimated for each of 3590 (1052 + 2538) patients, were used to assemble a matched cohort of 971 pairs of patients with consistent hypokalaemia vs. consistent normokalaemia, balanced on 54 baseline characteristics (mean age, 75 years; 60% women; 28% African American). We repeated the above process to assemble 2327 pairs of patients with discharge potassium <4.0 vs. 4.0–5.0 mmol/L and 449 pairs of patients with discharge serum potassium <3.5 vs. 4.0–5.0 mmol/L. Hazard ratios (HR) and 95% confidence intervals (CIs) associated with hypokalaemia were estimated in matched cohorts. 30 day all-cause mortality occurred in 5% and 4% of patients with consistent normokalaemia vs. consistent hypokalaemia, respectively (HR, 0.78; 95% CI, 0.52–1.18; P = 0.241). HRs (95% CI) for 30 day mortality associated with discharge serum potassium <4.0 and <3.5 mmol/L were 0.90 (0.70–1.16; P = 0.419) and 1.69 (0.94–3.04; P = 0.078), respectively. Hypokalaemia (<4.0 or <3.5 mmol/L) had no association with long-term mortality or other outcomes.

Conclusions In hospitalized older patients with HF, compared with normokalaemia (serum potassium 4.0–5.0 mmol/L), hypokalaemia (<4.0 or <3.5 mmol/L) had no significant associations with outcomes.

Keywords Heart failure; Potassium; Mortality; Hospitalization; Propensity score

Received: 17 October 2019; Revised: 26 January 2020; Accepted: 24 February 2020

*Correspondence to: Ali Ahmed, MD, MPH, Washington DC VA Medical Center, 50 Irving St. NW, Washington, DC 20422, USA. Tel: 1 202 745 8386; Email: ali.ahmed@va.gov

Introduction

Hypokalaemia is common in heart failure (HF) and is often attributed to the renal loss of potassium due to neurohormonal activation and use of diuretics. Potassium homeostasis is essential for resting transmembrane potential and maintenance of a normal cardiac rhythm, and hypokalaemia may increase the risk of ventricular arrhythmias and sudden cardiac death.1 In ambulatory patients with mild to moderate chronic HF, serum potassium levels <4.0 mmol/L have been shown to be associated with a higher risk of death.2–4 Sudden cardiac death is a more common mode of death in early stage mild to moderate HF, but with disease progression, death because of pump failure may become relatively more common.5–7 In the current study, we examined the association of hypokalaemia with clinical outcomes in hospitalized older patients with acute HF who would be expected to have more advanced disease.
Methods

Study design and patients

We conducted a nonrandomized propensity score-matched study of the Alabama Heart Failure Project, the details of which have been described previously. Briefly, 9649 medical records of fee-for-service Medicare beneficiaries discharged from 106 Alabama hospitals between 1998 and 2001 with a principle discharge diagnosis code of HF were abstracted. Charts of patients with dialysis, those transferred to another acute care hospital, or discharged against medical advice were excluded. Reliability of the abstraction process was assessed through internal and external reabstractions of 40 charts per month and had agreement values >80% and Kappa values >0.60. Extensive data on demographics, past medical history, medication use, hospital course, and discharge disposition were collected. The 9649 hospitalizations occurred in 8555 unique patients. Of the 8555 patients, 8049 were discharged alive. Of these, 7006 had data on both admission and discharge serum potassium levels.

Data on serum potassium

The Alabama Heart Failure Project is unique among large HF registries in that it collected data on admission and discharge serum potassium from laboratory reports, emergency room record, history and physical report, intensive care unit flow sheet, nursing flow sheet, diabetic flow sheets, graph sheet, and progress notes. We excluded 1125 patients whose admission or discharge serum potassium levels were >5.0 mmol/L as these values are associated with poor outcomes. The remaining 5881 patients had mean (±SD) admission and discharge serum potassium levels of 4.1 (±0.49) and 4.1 (±0.45) mmol/L, respectively. Among these patients, 1052 had consistent hypokalaemia, defined as both admission and discharge serum potassium <4.0 mmol/L, and 2538 had consistent normokalaemia, defined as both

![Flow chart displaying assembly of propensity score-matched cohorts of patients with heart failure by serum potassium.](image-url)

*Estimates of potassium cohort composition are approximate.*

---

ESC Heart Failure 2020; 7: 794–803
DOI: 10.1002/ehf2.12666
admission and discharge serum potassium levels 4.0–5.0 mmol/L (Figure 1A). Thus, our final prematch cohort consisted of 3590 patients, of whom 1052 had consistent hypokalaemia. These patients had mean (±SD) admission and discharge serum potassium levels of 4.2 (±0.48) and 4.2 (±0.45) mmol/L, respectively. Among the 1052 prematch patients with consistent hypokalaemia, 258 (25%) had a discharge serum potassium <3.5 mmol/L, and 15 (1.4%) had a discharge serum potassium <3.0 mmol/L. Of the 5881 patients with both admission and discharge serum potassium <5.0 mmol/L, only 82 (1.4%) had both admission and discharge serum potassium <3.5 mmol/L.

Study outcome

The primary outcome for the current study was all-cause mortality at 30 days, 1 year, and during overall follow-up of 8.8 (median, 3.3) years. Secondary outcomes included all-cause and HF readmissions, and the combined endpoints of all-cause readmission or all-cause mortality and HF readmission or all-cause mortality. All outcomes data were collected from Medicare data. Patients who were admitted to out-of-state hospitals or those who did not have Medicare pay for their hospitalizations were not included.

Assembly of a balanced cohort

Because patients with hypokalaemia and normokalaemia would have different baseline characteristics that could introduce bias, we used propensity scores to assemble a cohort in which these two groups of patients would be well-balanced on key measured baseline covariates.12,13 We estimated propensity scores of hypokalaemia for each of the 3590 patients using a nonparsimonious multivariable logistic regression model. In that model, hypokalaemia was the dependent variable, and all 54 baseline characteristics displayed in the Supporting Information, Figure S1, were included as covariates. In addition, the model was also adjusted for a significant interaction between discharge use of angiotensin-converting enzyme inhibitors and potassium supplements. No outcome variable was used in the model so that the process of assembling a balanced cohort was outcome blinded.

Using a greedy matching protocol, we were able to match 971 (92%) of the 1052 patients who had hypokalaemia with 971 patients with normokalaemia who had the same propensity scores between one and five decimal points.13 For example, if two patients had propensity scores of 0.12345 and 0.12346, then they would be rounded to 0.1235 and matched. Similarly, if they had propensity scores of 0.12342 and 0.12339, then they would be rounded to 0.1234 and matched. We then assessed balance in baseline characteristics of the postmatch cohort by estimating absolute standardized differences between the two potassium groups and presented them as a love plot (Figure S1).13 An absolute standardized difference of 0% indicates no residual bias and differences <10% are considered inconsequential.

Assembly of sensitivity cohorts

We repeated the above steps to assemble three sensitivity cohorts to determine if the results from our main cohort would vary if we used different definitions and approaches. First, we separately examined the associations of discharge serum potassium <4.0 and <3.5 mmol/L (regardless of admission serum potassium level), thus assembling two propensity score-matched cohorts of 4654 and 898 patients (Figure 1B and 1C). Then we examined the association of admission serum potassium <4.0 mmol/L (regardless of discharge serum potassium level), assembling a propensity score-matched cohort of 5084 patients (Figure 1D). The latter cohort also includes patients who died during index hospitalization to allow for assessment of in-hospital mortality.

Statistical analysis

Baseline characteristics of matched cohorts were compared using Pearson’s χ² and Wilcoxon rank sum tests, as appropriate. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for outcomes associated with hypokalaemia in matched cohorts. The association of hypokalaemia with all-cause mortality in the primary matched cohort was examined using Kaplan–Meier survival analysis. For survival analysis of mortality, for patients who died we estimated time to event from date of hospital discharge to date of death, and patients who survived were censored at hospital readmission or study end, whichever came first. For survival analysis of readmission, for those who were readmitted, time to event was estimated from date of hospital discharge to date of hospital readmission, and patients without a readmission were censored at death or study end, whichever came first.

To examine if there was a non-linear relationship between discharge serum potassium and all-cause mortality during 8.8 years of follow-up, we fitted restricted cubic spline models with three knots at serum potassium values 3.0, 3.5, 4.0 (reference), and 4.5 mmol/L using matched primary cohort data and prematch data adjusting for propensity scores. Subgroup analyses were conducted to assess potential heterogeneity of association between hypokalaemia and all-cause mortality in several subgroups of matched patients in the primary cohort. A two-tailed P value <0.05 was considered significant for all analyses. All statistical analyses were conducted using IBM SPSS Statistics for Windows software, version 24 (IBM Corp., Armonk, NY, USA), and SAS software for Windows, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results

Baseline characteristics

Matched patients \((n = 1942)\) had a mean age (±standard deviation) of 75 (±11) years, 60% were women, and 27% were African American. Before matching, patients with hypokalaemia were more likely to be younger, women, and African American but less likely to have coronary artery disease and diabetes. They were also more likely to have a higher mean systolic blood pressure, lower mean serum creatinine, and receive discharge prescriptions for potassium supplements but less likely to receive angiotensin-converting enzyme inhibitors, digoxin, and potassium-sparing diuretics (Table 1). These and other between-group differences in baseline characteristics were balanced after matching (Table 1; absolute standardized differences for all 54 baseline characteristics were <10% (Figure S2)). Among the 971
matched patients with consistent hypokalaemia, 229 (24%) had a discharge serum potassium <3.5 mmol/L, and 11 (1.1%) had a discharge serum potassium <3.0 mmol/L.

Admission and discharge hypokalaemia

30 day all-cause mortality occurred in 5% and 4% of matched patients with serum potassium levels 4.0–5.0 vs. <4.0 mmol/L at both admission and discharge, respectively (HR associated with hypokalaemia, 0.78; 95% CI, 0.52–1.18; \( P = 0.241 \); Table 2). The association of serum potassium <4.0 mmol/L with all-cause mortality remained unchanged during 1 year follow-up (Table 2) and 8.8 years of follow-up (Table 2 and Figure 2). Findings from our restricted cubic spline analysis demonstrate that there was no evidence of a non-linear relationship between serum potassium and all-cause mortality during 8.8 years of follow-up in the matched cohort (\( P \) for non-linearity, 0.15), but adjusted for propensity scores, the association appeared non-linear in the prematch cohort (\( P = 0.04 \); Figure 3). Consistent hypokalaemia had no significant association with all-cause readmission, HF readmission, or combined endpoints at any of the time points (Table 2).

Subgroup analyses

Findings of our subgroup analyses demonstrate that the association between serum potassium <4.0 mmol/L and 8.8 year mortality in our matched cohort was homogenous across various clinically relevant subgroups of patients except for by kidney function (\( P \) for interaction, 0.042; Figure S2). Among the 1120 matched patients with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m², all-cause mortality occurred in 68% and 69% of those with serum potassium 4.0–5.0 vs. <4.0 mmol/L, respectively (HR, 1.07; 95% CI, 0.93–1.23; \( P = 0.366 \)). In contrast, among the 822 matched patients with eGFR ≥60 mL/min/1.73 m², all-cause mortality occurred in 59% and 51% of those with potassium 4.0–5.0 vs. <4.0 mmol/L, respectively (HR, 0.84; 95% CI, 0.70–1.01; \( P = 0.061 \); Figure S2).

Findings from sensitivity cohorts

Consistent with findings from our primary cohort, findings from our sensitivity cohorts demonstrate that regardless of timing of serum potassium measurement (admission or discharge) or severity of hypokalaemia (<4.0 or <3.5 mmol/L), hypokalaemia had no association with mortality or other outcomes (Table 3).

Discussion

Findings from our study demonstrate that in older adults hospitalized for worsening HF, low serum potassium levels during hospitalization had no significant independent association with short-term or long-term outcomes. This lack of an association between hypokalaemia and poor outcomes in older hospitalized patients with acute HF is in contrast with the association of a higher risk of death observed in ambulatory

Table 2 Outcomes in 1942 propensity score-matched patients with heart failure by serum potassium levels

| % (number) of events | Both admission and discharge serum potassium (mmol/L) | Hazard ratio associated with serum potassium <4.0 mmol/L (95% confidence interval) |
|----------------------|------------------------------------------------------|----------------------------------------------------------------------------------|
| 30 days              |                                                     |                                                                                 |
| All-cause mortality  | 5% (51)                                             | 4% (40)                                                                          |
| All-cause readmission| 18% (172)                                           | 20% (190)                                                                        |
| Heart failure readmission | 6% (57)                          | 7% (69)                                                                          |
| All-cause readmission or all-cause mortality | 21% (205) | 22% (214)                                                                        |
| Heart failure readmission or all-cause mortality | 11% (102) | 10% (101)                                                                        | 0.78 (0.52–1.18); \( P = 0.241 \) |
| 1 year               |                                                     |                                                                                 |
| All-cause mortality  | 27% (264)                                           | 29% (285)                                                                        |
| All-cause readmission| 64% (623)                                           | 66% (643)                                                                        |
| Heart failure readmission | 31% (300)                      | 31% (299)                                                                        |
| All-cause readmission or all-cause mortality | 73% (704) | 74% (718)                                                                        | 1.10 (0.93–1.30); \( P = 0.260 \) |
| Heart failure readmission or all-cause mortality | 48% (469) | 50% (489)                                                                        | 1.09 (0.98–1.22); \( P = 0.129 \) |
| 8.8 years (median, 3.3 years) |                                           |                                                                                 |
| All-cause mortality  | 65% (627)                                           | 61% (596)                                                                        |
| All-cause readmission| 87% (847)                                           | 87% (844)                                                                        |
| Heart failure readmission | 59% (572)                      | 57% (554)                                                                        |
| All-cause readmission or all-cause mortality | 97% (938) | 96% (928)                                                                        | 1.00 (0.89–1.12); \( P = 0.993 \) |
| Heart failure readmission or all-cause mortality | 87% (845) | 87% (842)                                                                        | 1.03 (0.93–1.13); \( P = 0.574 \) |

ESC Heart Failure 2020; 7: 794–803
DOI: 10.1002/ehf2.12666
patients with chronic HF.\textsuperscript{2–4} These findings are important as they demonstrate that the relationship between hypokalaemia and outcomes is not homogenous in patients with HF and may vary according to patient characteristics. If these findings can be consistently replicated, that would suggest that it may not be necessary to strictly target serum potassium to values at or above 4.0 mmol/L in older patients hospitalized for decompensated HF.

One potential explanation for the lack of an independent association between hypokalaemia and outcomes in older patients hospitalized for HF in our study is that these patients have more advanced HF and thus are more likely to die from pump failure than from sudden cardiac death.\textsuperscript{5–7} In patients with mild to moderate HF in the MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure) trial, 58% of all deaths were sudden cardiac deaths, and 24% were pump failure deaths.\textsuperscript{5} In contrast, in patients with more advanced and symptomatic HF in the RALES (Randomized Aldactone Evaluation Study) trial, 29% of all deaths were sudden cardiac deaths, and 47% were pump failure deaths.\textsuperscript{5} In the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial that included relatively younger (mean age, 66 years) hospitalized HF patients, more deaths were due to pump failure (41%) than sudden
Table 3  Outcomes by serum potassium levels in propensity score-matched patients with heart failure in three sensitivity cohorts

| Serum potassium | Discharge only | Discharge only | Admission only* |
|-----------------|----------------|----------------|-----------------|
| N for matched cohort | 4654 | 898 | 5084 |
| Hypokalaemia | Serum potassium < 4.0 mmol/L | Serum potassium < 3.5 mmol/L | Serum potassium < 4.0 mmol/L |
| Normokalaemia | Serum potassium 4.0–5.0 mmol/L | Serum potassium 4.0–5.0 mmol/L | Serum potassium 4.0–5.0 mmol/L |

30 days
- All-cause mortality: 0.90 (0.70–1.16); P = 0.419; 1.69 (0.94–3.04); P = 0.078; 1.12 (0.93–1.35); P = 0.227
- All-cause readmission: 1.00 (0.88–1.14); P = 0.995; 0.81 (0.61–1.08); P = 0.146; 0.98 (0.86–1.11); P = 0.736
- Heart failure readmission: 1.08 (0.87–1.33); P = 0.502; 0.80 (0.51–1.25); P = 0.323; 0.92 (0.75–1.12); P = 0.396
- All-cause readmission or all-cause mortality: 0.99 (0.88–1.12); P = 0.871; 0.88 (0.68–1.15); P = 0.340; 1.01 (0.91–1.12); P = 0.906
- Heart failure readmission or all-cause mortality: 0.98 (0.83–1.16); P = 0.833; 1.01 (0.70–1.45); P = 0.967; 1.00 (0.87–1.15); P = 0.995

1 year
- All-cause mortality: 1.05 (0.95–1.16); P = 0.390; 1.17 (0.93–1.47); P = 0.179; 1.04 (0.94–1.15); P = 0.423
- All-cause readmission: 1.00 (0.93–1.07); P = 0.952; 0.98 (0.84–1.15); P = 0.834; 1.02 (0.95–1.09); P = 0.615
- Heart failure readmission: 0.94 (0.85–1.04); P = 0.250; 0.92 (0.74–1.15); P = 0.473; 1.01 (0.91–1.12); P = 0.835
- All-cause readmission or all-cause mortality: 1.00 (0.94–1.07); P = 0.972; 1.01 (0.87–1.17); P = 0.942; 1.02 (0.96–1.09); P = 0.461
- Heart failure readmission or all-cause mortality: 0.99 (0.91–1.07); P = 0.793; 1.09 (0.91–1.30); P = 0.348; 1.03 (0.96–1.11); P = 0.438

8.8 years (median, 3.3 years)
- All-cause mortality: 0.99 (0.93–1.07); P = 0.853; 1.05 (0.90–1.23); P = 0.533; 0.97 (0.91–1.04); P = 0.416
- All-cause readmission: 0.97 (0.91–1.03); P = 0.303; 0.97 (0.84–1.11); P = 0.624; 1.00 (0.94–1.06); P = 0.981
- Heart failure readmission: 0.92 (0.85–0.99); P = 0.025; 0.95 (0.80–1.13); P = 0.541; 0.99 (0.92–1.06); P = 0.754
- All-cause readmission or all-cause mortality: 0.97 (0.92–1.03); P = 0.331; 0.98 (0.86–1.12); P = 0.797; 1.01 (0.95–1.06); P = 0.862
- Heart failure readmission or all-cause mortality: 0.96 (0.90–1.02); P = 0.143; 1.02 (0.89–1.18); P = 0.764; 0.99 (0.94–1.05); P = 0.806

*Mortality in the cohort for admission hypokalaemia also includes in-hospital mortality. In-hospital mortality occurred in 4.7% and 4.3% of matched patients with admission serum potassium levels < 4.0 vs. 4.0–5.0 mmol/L, respectively (odds ratio associated admission serum potassium levels < 4.0 mmol/L; 1.11; 95% CI, 0.85–1.44; P = 0.457).
cardiac death (26%).\textsuperscript{7} If a higher proportion of hospitalized patients in our study had more advanced HF and died because of pump failure, then that would in part explain the lack of association of hypokalaemia with mortality. Further, nearly 60% of the patients in our study were women, in whom pump failure is a more common mode of death.\textsuperscript{16} Finally, a higher comorbidity burden in our older hospitalized patients with HF may mean a higher proportion of noncardiovascular death, which would be less likely to be affected by a low serum potassium level.\textsuperscript{6}

Findings from our study need to be interpreted with caution and not be used to underestimate the risk associated with very low serum potassium. Compared with discharge serum potassium 4.0–5.0 mmol/L, a discharge serum potassium <3.5 mmol/L was associated with a near-significant 69% higher risk of 30 day all-cause mortality. Findings from our spline plot analyses also suggest an incrementally higher risk of death with serum potassium under 3.5 mmol/L and specifically under 3.0 mmol/L. However, these data are extrapolated from a very small number of patients as only 0.4% (15/3590) of prematch, and 0.6% (11/1942) of matched patients in our study had a discharge serum potassium <3.0 mmol/L. These proportions would be expected to be even lower in contemporary patients with HF as a greater proportion of those patients would be receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, drugs known to increase serum potassium levels. Thus, although the risk of very low serum potassium is high at an individual patient level, its attributable risk would be expected to be low at a population level.

While findings of subgroup analyses generally need to be considered exploratory,\textsuperscript{17} the significant interaction between hypokalaemia and kidney function in older patients hospitalized for acute HF is intriguing and deserves further discussion. We have previously observed a similar significant interaction ($P = 0.047$) between hypokalaemia and kidney function in ambulatory younger patients with chronic HF.\textsuperscript{2} In that study, of the 2374 propensity score-matched patients, 1062 had eGFR <60 mL/min/1.73 m$^2$, and among these patients, all-cause mortality occurred in 38% and 48% of those with serum potassium 4.0–5.5 vs. <4.0 mmol/L, respectively (HR, 1.40; 95% CI, 1.16–1.68; $P < 0.001$) and respective rates among the 1312 matched patients with eGFR $\geq$60 mL/min/1.73 m$^2$ were 27% and 29% (HR, 1.05; 95% CI, 0.86–1.29; $P = 0.569$).\textsuperscript{2} Patients with impaired kidney function are more likely to have higher serum potassium levels; therefore, hypokalaemia in the setting of impaired kidney function may be the result of unusual electrolyte or acid–base disturbances that also increase their risk for adverse outcomes.\textsuperscript{4}

Several studies have examined the association of hypokalaemia and outcomes in hospitalized patients with HF.\textsuperscript{18–20} In one study, admission serum potassium levels had no independent association with outcomes in two cohorts of patients hospitalized for acute HF.\textsuperscript{18} In another study, 77 patients had discharge serum potassium <3.5 mmol/L that was associated with a higher risk of death.\textsuperscript{19} When adjusted for the ‘entire collection of potassium values per patient’, serum potassium 3.5 mmol/L had no significant association with poor outcomes, though values of 3.0 and 2.5 mmol/L had. However, it is not clear how many of the 77 had serum potassium consistently at 3.5, 3.0, and 2.5 mmol/L during follow-up.\textsuperscript{19} In the study that reported a significant association between hypokalaemia and higher risk of inpatient mortality, hypokalaemia was defined by discharge International Classification of Diseases codes.\textsuperscript{20} In contrast to that study, our study is based on patients who had normal or low serum potassium at both admission and discharge. In addition, our sensitivity analyses separately examined the associations of admission and discharge hypokalaemia as well as more severe discharge hypokalaemia with outcomes in separately assembled propensity score-matched cohorts.

The findings of our study are important as they suggest that the prognostic implication of hypokalaemia in older patients hospitalized for HF may differ from that in ambulatory patients with chronic HF. If these findings can be replicated in more contemporary populations of HF with longitudinal data on serum potassium, that would suggest that serum potassium levels $\geq$3.5 mmol/L may be safe in hospitalized patients with decompensated HF.

Our study has several limitations. These data are based on HF patients hospitalized over 20 years ago, which may limit generalizability. However, many important patient characteristics in our study such as age and ejection fraction are similar to a study based on more contemporary patients.\textsuperscript{19} The prevalence of hypokalaemia was lower in that study (3.6% vs. 6.8% in our study), which is likely because of a higher use of neurohormonal antagonists known to raise serum potassium levels in that study. Another limitation of our study is the lack of data on serum potassium during follow-up. However, evidence suggests that most patients with HF who had hypokalaemia during hospitalization remain hypokalaemic during follow-up.\textsuperscript{19} We also did not have data on cause of death. Finally, residual measured and unmeasured confounding may have influenced the findings.

Conclusions

In older patients hospitalized for decompensated HF, compared with a normal serum potassium level of 4.0–5.0 mmol/L, serum potassium values <4.0 or <3.5 mmol/L had no significant association with short-term or long-term mortality or readmission. Additional studies are needed to

ESC Heart Failure 2020; 7: 794–803
DOI: 10.1002/ehf2.12666
further evaluate the relationship between serum potassium levels and outcomes among hospitalized patients with HF.

Conflict of interest

S.D.A reports consulting honoraria from Servier, Novartis, St. Jude Medical, Bayer, Boehringer Ingelheim, and Vifor Pharma. M.V., S.P., P.H.L., C.F., C.A., Y.C., R.M.A., S.V.H., and A.A. have nothing to declare.

Funding

This work was in part supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (Grants R01-HL085561, R01-HL085561-S, and R01-HL097047 to A.A.) and by the German Centre for Cardiovascular Research (to M.V.).

References

1. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004; 43: 155–161.
2. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007; 28: 1334–1343.
3. Alper AB, Campbell RC, Anker SD, Bakris G, Wahle C, Love TE, Hamm LL, Mujib M, Ahmed A. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol 2009; 137: 1–8.
4. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 2010; 3: 253–260.
5. Carson P, Anand I, O’Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Barnett JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2329–2334.
6. Zile MR, Gaasch WH, Anand IS, Haas M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Investigators IP. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I Preserve) trial. Circulation 2010; 121: 1393–1405.
7. O’Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Pina I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M. Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan i. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010; 159: 841–849 e1.
8. Feller MA, Mujib M, Zhang Y, Ekundayo OJ, Aban IB, Fonarow GC, Allman RM, Ahmed A. Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project. Int J Cardiol 2012; 162: 39–44.
9. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell’Italia LJ, Bakris GL, Rich MW. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med 2012; 125: 399–410.
10. Ahmed A, Bourge RC, Fonarow GC, Patel K, Morgan CJ, Fleg JL, Aban IB, Love TE, Yancy CW, Deedwania P, van Veldhuisen DJ, Filippatos GS, Anker SD, Allman RM. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med 2014; 127: 61–70.
11. Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE, Aronow WS, Ahmed A. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol 2010; 144: 383–388.
12. Rosenbaum PRRD. The central role of propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–55.
13. Rubin DB. Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001; 2: 169–188.
14. Ahmed MI, White M, Ekundayo OJ, Love TE, Aban I, Liu B, Aronow WS, Ahmed A. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J 2009; 30: 2029–2037.
15. Wahle C, Adamopoulos C, Ekundayo OJ, Mujib M, Aronow WS, Ahmed A. A propensity-matched study of outcomes of chronic heart failure (HF) in younger and older adults. Arch Gerontol Geriatr 2009; 49: 165–171.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Love plot displaying absolute standardized differences comparing 54 baseline characteristics in patients with heart failure by serum potassium < 4.0 mmol/L versus 4.0–5.0 mmol/L before and after propensity score matching. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers.

Figure S2. Hazard ratios and 95% confidence intervals (CI) for all-cause mortality associated with serum potassium < 4.0 (versus 4.0–5.0) mmol/L in subgroups of propensity score-matched patients with heart failure. BP, blood pressure; GFR, glomerular filtration rate; EF, ejection fraction; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers.
16. Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, Maggioni AP, Carson PE, Swedberg K, Levy WC. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation 2012; 126: 2402–2407.

17. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176–186.

18. Tromp J, Ter Maaten JM, Damman K, O’Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials). Am J Cardiol 2017; 119: 290–296.

19. Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, Minana G, Santas E, Chorro FJ, Mollar A, Carratala A, Navarro J, Gorriz JL, Luis J, Husser O, Metra M, Sanchis J. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation 2018; 137: 1320–1330.

20. Basnet S, Dhital R, Tharu B, Ghimire S, Poudel DR, Donato A. Influence of abnormal potassium levels on mortality among hospitalized heart failure patients in the US: data from National Inpatient Sample. J Community Hosp Intern Med Perspect 2019; 9: 103–107.